A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.

SCHOTT Pharma has announced an investment of €100m ($114m) to expand its manufacturing capacity for sterile RTU cartridges.

The alert comes amid some patients accessing GLP-1RAs through unregulated channels, where safety information is often not ...

Juvenescence has acquired Ro5 to enhance its AI/machine learning capabilities and improve research and development.

China’s NMPA has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to treat persistent, recurrent or metastatic ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) ...

Italy’s Axxam and Molecular Health have partnered to identify and validate new therapeutic targets in drug development.

Digital innovations such as ePRO and eCOA are streamlining clinical trials, boosting participant engagement, and improving ...

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease ...